28th Feb 2014 10:51
LONDON (Alliance News) - Inhaler company Vectura Group PLC Friday said its partner Sandoz has received marketing approval for its AirFluSal Forspiro inhaler for treating asthma and chronic obstructive pulmonary disease, the first approval for the product in Asia.
Vectura developed the product and licensed it to Sandoz in 2006. It currently has approval in Denmark, Germany, Belgium, Sweden, Norway, Hungary, Romania and Bulgaria, and has been launched in Denmark and Germany.
South Korea has approved the 50 microgram to 250 microgram and 50 microgram to 500 microgram dosage forms for the continuous treatment of patients above 12 years of age with persistent asthma or for symptomatic treatment of COPD, Vectura said in a statement.
Vectura shares were up 0.2% at 161.75 pence Friday morning.
By Steve McGrath; [email protected]; @SteveMcGrath1
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
VEC.L